Gene expression library

Horizon Discovery has introduced Edit-R CRISPRa arrayed CRISPR RNA (crRNA) libraries, the latest addition to its CRISPR activation (CRISPRa) reagent platform from the recently acquired Dharmacon business. The new libraries offer a powerful tool for drug discovery, pathway analysis and disease progression studies.

Unlike lentiviral pooled screens, Edit-R synthetic crRNA arrayed libraries enable one-gene-per-well investigation, using high-content assays to answer more in-depth biological questions. A CRISPRa-based system for overexpression studies also overcomes many of the shortcomings of early generations of DNA plasmid-encoded gene expression tools. By triggering the endogenous gene’s expression, the gene is transcribed in its native form, so researchers can be assured of highly relevant results in their cell system.

The Edit-R CRISPRa portfolio includes catalogue libraries for popular human and mouse gene families, such as ubiquitin enzymes, transcription factors, and kinases, in addition to drug-targeted genes and the whole human genome. Bespoke collections are also available to support researchers working with a specialised gene target list.

More information on Horizon’s CRISPRa reagents and screening services is available online.

www.horizondiscovery.com/research-services/functional-genomicscreening/crispr-screening

 

 

Other news

Learning from history

Upcoming Events

Lab Innovations

NEC, Birmingham (Hall 12)
30-31 October 2019

British Society for Immunology Congress

Arena and Convention Centre, Kings Dock, Liverpool Waterfront, Liverpool L3 4FP
2-5 December 2019

The genomic and molecular revolution in microbiology: in technology we trust (or do we?).

RAF Museum, Hendon, London
14 May 2020

Clinical and Laboratory Haemostasis 2020

STEM/Atrium Conference Centre, Sheffield Hallam University
3-4 June 2020

Latest Issue

Pathology In Practice

Pathology In Practice

Oct 2019

Are you ready for the winter influenza season?

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.